AWS
TRIB

Atria Wealth Solutions’s Trinity Biotech TRIB Stock Holding History

Atria Wealth Solutions’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-229
Closed -$32.2K – 1988
2023
Q1 		$32.2K Hold
229
– – ﹤0.01% 1822
2022
Q4 		$34K Buy
229
+64
+39% +$11.6K ﹤0.01% 1765
2022
Q3 		$26.5K Hold
165
– – ﹤0.01% 1721
2022
Q2 		$30K Sell
165
-5
-3% -$916 ﹤0.01% 1604
2022
Q1 		$27K Buy
+170
New +$29.4K ﹤0.01% 1714

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $514M AUM 29.58% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Atria Wealth Solutions's TRIB Position: Q2 2023 in Review

Atria Wealth Solutions sold out of Trinity Biotech (TRIB) in Q2 2023, closing a stake of 229 shares — an estimated $32.2K sold.

Atria Wealth Solutions first reported a position in TRIB in Q1 2022 and held it in 5 quarters. The position peaked at $34K in Q4 2022. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2023.

  • Atria Wealth Solutions reported no remaining Trinity Biotech position as of Q2 2023 after selling out during the quarter.
  • Atria Wealth Solutions sold 229 Trinity Biotech shares in Q2 2023, an estimated $32.2K.
  • Atria Wealth Solutions first reported a position in Trinity Biotech in Q1 2022 and held it in 5 quarters.
  • Atria Wealth Solutions's Trinity Biotech position peaked at $34K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2023.

Based on Atria Wealth Solutions's 13F filing for Q2 2023, filed 3 Aug 2023.